CHCWM – Cancer & Hematology Centers of West Michigan

IK-930-001  (Ikena)

Description:  A Phase 1, First-In-Human Study of IK-930, An oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors

Mechanism of ActionTEAD Inhibitor Targeting the Hippo Pathway.  Markers of aberrant Hippo pathway include YAP/TAZ gene alterations or NF2 loss of function mutations/deletions.  Cancers of special interest include – malignant pleural mesothelioma, epithelial hemangioendothelioma regardless of above mutational markers.

Target Patient Population:  All solid tumors

Study Design:  Study Drug is given orally.